IL311711A - Treatment of lightning using Ru-12 guanine nucleotide exchange factor inhibitors - Google Patents

Treatment of lightning using Ru-12 guanine nucleotide exchange factor inhibitors

Info

Publication number
IL311711A
IL311711A IL311711A IL31171124A IL311711A IL 311711 A IL311711 A IL 311711A IL 311711 A IL311711 A IL 311711A IL 31171124 A IL31171124 A IL 31171124A IL 311711 A IL311711 A IL 311711A
Authority
IL
Israel
Prior art keywords
arhgef12
glaucoma
inhibitors
treatment
guanine nucleotide
Prior art date
Application number
IL311711A
Other languages
English (en)
Hebrew (he)
Inventor
Aris Baras
Giovanni Coppola
Manuel Allen Revez Ferreira
Lauren Gurski
Kavita Praveen
Claudia Schurmann
Original Assignee
Regeneron Pharma
Aris Baras
Giovanni Coppola
Manuel Allen Revez Ferreira
Lauren Gurski
Kavita Praveen
Claudia Schurmann
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma, Aris Baras, Giovanni Coppola, Manuel Allen Revez Ferreira, Lauren Gurski, Kavita Praveen, Claudia Schurmann filed Critical Regeneron Pharma
Publication of IL311711A publication Critical patent/IL311711A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
    • C08G69/02—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids
    • C08G69/08—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids derived from amino-carboxylic acids
    • C08G69/10—Alpha-amino-carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/34—Allele or polymorphism specific uses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)
  • Polymers & Plastics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL311711A 2021-09-30 2022-09-28 Treatment of lightning using Ru-12 guanine nucleotide exchange factor inhibitors IL311711A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163250492P 2021-09-30 2021-09-30
PCT/US2022/077176 WO2023056295A1 (en) 2021-09-30 2022-09-28 Treatment of glaucoma with rho guanine nucleotide exchange factor 12 (arhgef12) inhibitors

Publications (1)

Publication Number Publication Date
IL311711A true IL311711A (en) 2024-05-01

Family

ID=83996920

Family Applications (1)

Application Number Title Priority Date Filing Date
IL311711A IL311711A (en) 2021-09-30 2022-09-28 Treatment of lightning using Ru-12 guanine nucleotide exchange factor inhibitors

Country Status (9)

Country Link
US (1) US12577562B2 (cg-RX-API-DMAC7.html)
EP (1) EP4408535A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024535110A (cg-RX-API-DMAC7.html)
KR (1) KR20240099232A9 (cg-RX-API-DMAC7.html)
CN (1) CN118891050A (cg-RX-API-DMAC7.html)
AU (1) AU2022357497A1 (cg-RX-API-DMAC7.html)
CA (1) CA3232251A1 (cg-RX-API-DMAC7.html)
IL (1) IL311711A (cg-RX-API-DMAC7.html)
WO (1) WO2023056295A1 (cg-RX-API-DMAC7.html)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004045644A1 (ja) 2002-11-18 2004-06-03 Santen Pharmaceutical Co., Ltd. Rhoキナーゼ阻害剤とβ遮断薬からなる緑内障治療剤
WO2006104751A2 (en) * 2005-03-30 2006-10-05 The Regents Of The University Of Michigan Methods and compositions for modulating rho-mediated gene transcription
AR057252A1 (es) 2005-12-27 2007-11-21 Alcon Mfg Ltd Inhibicion de rho quinasa mediada por arni para el tratamiento de trastornos oculares
GB201107176D0 (en) * 2011-04-28 2011-06-15 Cxr Biosciences Ltd Pyrrolnitrin derivatives
JP2022508715A (ja) 2018-10-15 2022-01-19 オキュフィア・ファーマ・インコーポレイテッド 緑内障および関連状態の処置のための方法および組成物
CA3126476A1 (en) * 2019-01-23 2020-07-30 Regeneron Pharmaceuticals, Inc. Treatment of ophthalmic conditions with angiopoietin-like 7 (angptl7) inhibitors

Also Published As

Publication number Publication date
CN118891050A (zh) 2024-11-01
AU2022357497A1 (en) 2024-04-04
US12577562B2 (en) 2026-03-17
KR20240099232A9 (ko) 2025-12-10
CA3232251A1 (en) 2023-04-06
JP2024535110A (ja) 2024-09-26
WO2023056295A1 (en) 2023-04-06
US20230099109A1 (en) 2023-03-30
EP4408535A1 (en) 2024-08-07
KR20240099232A (ko) 2024-06-28

Similar Documents

Publication Publication Date Title
JP1742743S (ja) 基板処理チャンバのための回転防止プロセスキット用バッフル
PE20180279A1 (es) Derivados de 2-(pirazolopiridin-3-il)pirimidina como inhibidores de jak
ZA202503575B (en) Novel prmt5 inhibitor and use thereof
MX2023002324A (es) Tratamiento de trastornos de perdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados.
DE60036540D1 (de) Rho-kinase-inhibitoren für die vorbeugung oder behandlung von interstitieller pneumonie und pulmonaler fibrose
WO2013040528A1 (en) Antimicrobial compounds
MX2017010230A (es) Derivados de mono- y poliazanaftaleno sustituidos y su uso.
PL2250172T3 (pl) Pirolopirazynowe inhibitory kinazy
EP2234618A4 (en) BENZOPYRANE AND ANALOGUE AS RHO KINASE INHIBITORS
MX2009006756A (es) Derivados de 1-amino-metil-l-fenil-ciclohexano como inhibidores de dpp-iv.
EA201000848A1 (ru) Ингибиторы протеинкиназы и их применение
CY1116043T1 (el) Κρυσταλλικες μορφες υδροχλωρικου αλατος (4α-r,9α-s)-1-(1η-βενζοϊμιδαζολο-5-καρβονυλ)2,3,4,4α,9,9α-εξαϋδρο-1η-ινδενο[2,1-β]πυριδινο-6-καρβονιτριλιου και χρηση τους ως αναστολεις της hsd 1
HK40113128A (en) Treatment of glaucoma with rho guanine nucleotide exchange factor 12 (arhgef12) inhibitors
KR20240099232A9 (ko) Rho 구아닌 뉴클레오타이드 교환 인자 12[Rho Guanine Nucleotide Exchange Factor 12, ARHGEF12] 억제제를 이용한 녹내장 치료
Wang et al. Synthesis, SAR study and biological evaluation of novel pyrazolo [1, 5-a] pyrimidin-7-yl phenyl amides as anti-proliferative agents
Tunçbilek et al. Synthesis and antimicrobial evaluation of some new substituted purine derivatives
MX2010005787A (es) Derivados de imizado-tiazole en la forma de inhibidores de cinasa de proteina.
HK1212212A1 (en) Compositions and methods for inhibiting activity of hypoxia-inducible transcription factor complex and its use for treatment of tumors
MX2026000476A (es) Sales clorhidrato cristalinas micronizadas de compuestos inhibidores antiviricos de la helicasa-primasa
CU20250003A7 (es) Compuestos de piridinona sustituida como inhibidores de cbl-b
CL2025003529A1 (es) Nuevos polimorfos de (s)-6-cloro-2,3,4,9-tetrahidro-1h-carbazol-1-carboxamida en forma cristalina.
BRPI0508927A (pt) compostos úteis para o tratamento de doenças
WO2023230478A3 (en) Treatment of sos2 related diseases and disorders
TW200639155A (en) Thiazolidinones, their production and use as pharmaceutical agents
EA201992341A8 (ru) Применение производного глутаримида для лечения заболеваний, связанных с аберрантной активностью цитокинов